StocksRunner logo
mail
search
 
menu
 
Sanofi
$49.52
-0.94%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 

SNY Stock Analysis & IQ Rating | Sanofi

 
 
 

SNY

 

Sanofi

$49.52

 
-$0.47 | -0.94%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 60.12
 
 
MKT CAP
$ 122.50B
 
52W Low
$ 44.62
 
 
VOL
$ 2.79M
 
P/E Ratio
11.63
 
 
AVG VOL
$ 3.52M
 
RSI
 
 
TREND
 
 
 

SNY Stock IQ

 
lock  Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

SNY Target Price

 
 
 

Strengths

 

SNY Rewards

 Earnings are forecast to grow

SNY Rewards

 Trading below its fair value

 
 

Chart

 
 

$45.54   (+8.74%)

$45.66   (+8.45%)

$49.19   (+0.67%)

$51.26   (-3.39%)

 
 
1year
6month
3month
1month
 

SNY Risk Level

 

SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

 
 

Risks Indicators

 

 Investors losing confidence

 
 
SNY Risk Level
LOW
HIGH
 

SNY Analysts Opinion

 

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

 
 

Earnings

×
 

Earnings

 

SNY Earnings Sentiment

 Reported a strong earnings

SNY Earnings Sentiment

 Earnings decline YoY

 
 

Rating

×
 

Rating

 
 

Momentum

×
 

Momentum

 

SNY Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 

SNY Future Sentiment

 Earnings are forecast to grow

SNY Future Sentiment

 Trading below its fair value

 
 

SNY Analysts Opinion

SNY Analysts opinion is negative and it remained unchanged from the past 3 months

 

SNY Street Consensus

 

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
90%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
33%
100%
 

SNY Street Opinion 

SNY Street view is extremely bullish and have positive views on the near-term outlook

 

SNY Performance Sentiment

 
Sentiments overview associated with SNY events and the stock performance.
 
90%
10%
Positive
Negative
26 out of 29
events present
3 out of 29
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 

Technical Price Levels

 

Average key support and resistance price levels.

 
lock  Login to display
 
Support
Price
 
$50.62
 
Resistance
Price
 
$45.07
 
 
Current Price Range
 
$50.90
 
 
Show methods +
 
 

SNY Earnings

 

The TTM reflects 12-month period, providing review of SNY financial performance.

 
Millions of Dollars
TTM
2024
2023
CAGR
 

 
Total Revenue
45,738
44,286
41,618
+4.83%
 
 
Cost of Revenue
13,120
13,205
12,628
+1.93%
 
 
Gross Profit
32,618
31,081
28,990
+6.07%
 
 
Operating Exp
22,637
21,619
19,815
+6.88%
 
 
Operating Inc
9,981
9,462
9,175
+4.30%
 
 
Net Interest Inc
-432
-560
-706
-
 
 
Interest Exp
665
749
710
-3.22%
 
 
Interest Inc
336
413
527
-20.15%
 
 
Other Inc Exp
-1,731
-2,204
-2,218
-
 
 
EPS Growth
3.69
2.22
2.15
+31.01%
 
 

SNY Financial Health

 

The company financial health has shown minor improvement, but significant issues remain

 

Financial Score

 
3.42
 
Next Earnings Date: Oct 24, 2025
 
 
Linked to SNY
IQ
Close Price
Change

 

PFE

4.06

24.67

-0.22%

 

NVS

4.26

131.64

+0.15%

 

LLY

4.15

821.04

+1.06%

 

MRK

4.03

87.18

-0.55%

 

ABBV

4.14

228.25

-0.16%

 
 
 
SNY Latest Analysis +
 
 
FAQ About SNY Stock Insights
 

What is SNY current stock price?

What are SNY stock strengths?

What risks are associated with SNY stock?

When is SNY next earnings report?

What is SNY market cap and volume?

What is SNY's current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

 
 
StocksRunner

Explore our SNY Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored SNY Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our SNY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner Overview
 
StocksRunner Trending
 
StocksRunner Screener
 
StocksRunner Insights
 
StocksRunner Top Rated
 
StocksRunner Momentum
 
StocksRunner Earnings
 
StocksRunner Leaders
mail
 
 

SNY

 

Sanofi

 
 

Current Price

 

$49.52

 
-$0.47 | -0.94%
 
 
52W High
$ 60.12
 
 
MKT CAP
$ 122.50B
 
52W Low
$ 44.62
 
 
VOL
$ 2.79M
 
P/E Ratio
11.63
 
 
AVG VOL
$ 3.52M
 
RSI
 
 
TREND
 
 
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 

Target Price

 
 
 
 
Not Enough Information
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

SNY Rewards

 Earnings are forecast to grow

SNY Rewards

 Trading below its fair value

 
 
 
 
 

SNY Stock IQ

 
lock  Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 

Chart

 
 

$45.54   (+8.74%)

$45.66   (+8.45%)

$49.19   (+0.67%)

$51.26   (-3.39%)

 
 
1year
6month
3month
1month
 

SNY Analysts Opinion

 

SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

 
 

Earnings

×
 

Earnings

 

SNY Earnings Sentiment

 Reported a strong earnings

SNY Earnings Sentiment

 Earnings decline YoY

 
 

Rating

×
 

Rating

 
 

Momentum

×
 

Momentum

 

SNY Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 

SNY Future Sentiment

 Earnings are forecast to grow

SNY Future Sentiment

 Trading below its fair value

 
 

SNY Analysts Opinion

SNY Analysts opinion is negative and it remained unchanged from the past 3 months

 

SNY Street Consensus

 

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
90%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
33%
100%
 

SNY Street Opinion 

SNY Street view is extremely bullish and have positive views on the near-term outlook

 

SNY Risk Level

 

SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

 
 

Risks Indicators

 

 Investors losing confidence

 
 
SNY Risk Level
LOW
HIGH
 
SNY Performance Sentiment
 
Sentiments overview associated with SNY events and the stock performance.
 
90%
10%
Positive
Negative
26 out of 29
events present
3 out of 29
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

Technical Price Levels

 

Average key support and resistance price levels.

 
lock  Login to display
 
Support
Price
 
$50.62
 
Resistance
Price
 
$45.07
 
 
Current Price Range
 
$50.90
 
 
Show methods +
 
 

SNY Earnings

 

The TTM data reflects the most recent 12-month period, providing overview of SNY financial performance.

 
Millions of Dollars
TTM
2024
2023
CAGR
 

 
Total Revenue
45,738
44,286
41,618
+4.83%
 
 
Cost of Revenue
13,120
13,205
12,628
+1.93%
 
 
Gross Profit
32,618
31,081
28,990
+6.07%
 
 
Operating Exp
22,637
21,619
19,815
+6.88%
 
 
Operating Inc
9,981
9,462
9,175
+4.30%
 
 
Net Interest Inc
-432
-560
-706
-
 
 
Interest Exp
665
749
710
-3.22%
 
 
Interest Inc
336
413
527
-20.15%
 
 
Other Inc Exp
-1,731
-2,204
-2,218
-
 
 
EPS Growth
3.69
2.22
2.15
+31.01%
 
 

SNY Financial Health

 

The company financial health has shown minor improvement, but significant issues remain

 

Financial Score

 
3.42
 
Next Earnings Date: Oct 24, 2025
 
 
 
 
 

SNY Latest Analysis

 
 
 

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy. ) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537 formerly known as INBRX-101) for alpha-1 antitrypsin .AATD causes emphysema when the body doesn’.t produce enough of the protective alpha-1 antitrypsin (AAT) protein leading to a breakdown of the lung’.s air sacs (alveoli).This genetic condition leads to the accumulation of enzymes such as neutro

 

Wed Oct 22, 2025

$49.99 | +0.66%
 
Activity
Potential

Sanofis Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537 formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-

 

Wed Oct 22, 2025

$49.99 | +0.66%
 
Activity

Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine . (RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.

 

Mon Oct 20, 2025

$49.73 | -1.76%
 
Potential

Sanofi: FDA Accepts SBLA For Tzield For Expedited Review . (RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D.

 

Mon Oct 20, 2025

$49.73 | -1.76%
 
Activity

Sanofis Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease. On Friday the European Medicines Agency'.s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for ) Rezurock (belumosudil).The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic .cGVHD is considered one of the leading causes of morbidity and late non-relapse mortality after stem cell transplant. Sanofi will seek a

 

Fri Oct 17, 2025

$50.62 | +1.19%
 
Activity
Activity
Momentum

Sanofis Wayrilz Bags CHMP Recommendation For Immune Thrombocytopenia Treatment . (RTTNews) - Sanofi (SNY) Friday announced that the European Medicines Agencys Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of immune thrombocytopenia in adults.

 

Fri Oct 17, 2025

$50.62 | +1.19%
 
Activity

EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi. ...

 

Thu Oct 16, 2025

$50.02 | +2.17%
 
Activity

EVOQ Enters Collaboration And License Agreement With Sanofi . (RTTNews) - EVOQ Therapeutics Inc. announced a Collaboration and License Agreement with Sanofi (SNY). EVOQ is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQs technology platform utilizes a synthetic HDL NanoDisc that

 

Thu Oct 16, 2025

$50.02 | +2.17%
 
Activity

RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes. Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection expanding its reach beyond rare diseases.

 

Thu Oct 9, 2025

$48.82 | +0.04%
 
Activity

BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS. ) (FRA: 5LB) (OTCQB:) (".BioVaxys". or ".Company".) is pleased to announce that Dr. Tartaglia is an internationally recognized vaccine R&.D leader with over 34 years of industry experience including contributions to partnerships with private sector government and international agencies.  Dr. Tartaglia recently retired as Global Head of Vaccine Development and Life Cycle Management for Sanofi the global p

 

Wed Oct 8, 2025

$48.80 | -0.80%
 
Activity

 
 
 
 
 
StocksRunner

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNY. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our SNY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

SNY Runner Alarm

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 

 
 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing SNY

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing SNY

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.